Reverie Labs Raises $25M in Series A Funding
Summary
Reverie Labs, a Cambridge, Mass.-based pharmaceutical company pioneering the application of machine learning to developing next-generation small molecule kinase inhibitors, closed its $25M Series A financing. In conjunction with the financing, which brings the total capital raised to more than $32M, Wayne Holman, M.D., founder and CEO of Ridgeback Capital, joined Reverie’s Board of Directors. The company will use the proceeds to advance its internal and partnered drug discovery programs towards the clinic, further develop its innovative computational discovery platform, and grow its cross-disciplinary team of scientists and engineers. Led by Jonah Kallenbach, co-founder and CEO, and Ankit Gupta, co-founder and CTO, Reverie is a pharmaceutical company leveraging machine learning, physics-based modeling, and massive-scale computational infrastructure to engineer new medicines. The technology consists of predictive tools, new methods for focused molecular generation, and a scalable cloud framework, which allows for the unhindered exploration of chemical space.
Funding
Review available funding amount, funding date, investors, and linked company information related to Reverie Labs Raises $25M in Series A Funding in the interactive ISVWorld profile.